Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Pre-Market Stock Futures: The futures are trading higher on Wednesday after a stellar day across Wall Street on Tuesday. All of the major indices finished the day higher, with the technology-heavy NAS
Edgestream Partners L.P. Has $5.45 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN
04:28am, Wednesday, 03'rd Dec 2025
Edgestream Partners L.P. boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 361.2% during the second quarter, according to its most recent disclosure with the Securities and Exc
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript
04:53pm, Tuesday, 02'nd Dec 2025
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript
REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD
03:25pm, Tuesday, 02'nd Dec 2025
Regeneron teams up with Tessera to advance TSRA-196, aiming to correct the genetic cause of AATD as preclinical data support its move toward trials.
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
10:51am, Monday, 01'st Dec 2025
Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.
TARRYTOWN, N.Y. and SOMERVILLE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Tessera Therapeutics, Inc., today announced a global collaboration to develop
Should You Buy This Biotech Stock That Just Gained 5% in 1 Day?
11:15pm, Sunday, 30'th Nov 2025
Sales of Regeneron Pharmaceuticals' Eylea have declined over the past few quarters due to competition. However, the company launched a new formulation of the medicine that just earned another label ex
Regeneron (REGN) Up 20.2% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 27'th Nov 2025
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
11:46am, Tuesday, 25'th Nov 2025
Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.
Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years a
The shortened holiday week is here, and the futures are trading higher this morning.
1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month
07:58am, Monday, 24'th Nov 2025
Markets are dipping lower this month, but positive news from the FDA has this biotech stock ripping higher.
Bank Julius Baer & Co. Ltd Zurich Sells 1,845 Shares of Regeneron Pharmaceuticals, Inc. $REGN
04:07am, Sunday, 23'rd Nov 2025
Bank Julius Baer and Co. Ltd Zurich trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 62.8% in the second quarter, according to the company in its most recent Form 13F filing w
AXQ Capital LP Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN
04:07am, Sunday, 23'rd Nov 2025
AXQ Capital LP lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 123.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Ex
